HIGHLIGHTS
- who: Edward S. Kim from the Orlando, FL, USA Northwestern University have published the article: Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial, in the Journal: (JOURNAL) of 26/07/2019
- what: The authors report the final analysis of B-F1RST which included OS after long-term (>3-year) follow-up updated results for the non-biomarker-evaluable patients12 and additional exploratory biomarker analyses of the genomic landscape and association of the most prevalent alterations with bTMB and efficacy outcomes. greater . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.